DC
PHAT icon

Decheng Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Decheng Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-694,254
Closed -$5.64M – 29
2024
Q4 		$5.64M Sell
694,254
-555,746
-44% -$6.88M 1.21% 16
2024
Q3 		$22.6M Buy
1,250,000
+400,000
+47% +$5.59M 5.35% 3
2024
Q2 		$8.76M Hold
850,000
– – 2.68% 9
2024
Q1 		$9.03M Hold
850,000
– – 1.21% 10
2023
Q4 		$7.76M Buy
+850,000
New +$7.32M 2.17% 13

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Decheng Capital's PHAT Position: Q1 2025 in Review

Decheng Capital sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 694,254 shares — an estimated $5.64M sold.

Decheng Capital first reported a position in PHAT in Q4 2023 and held it in 5 quarters. The position peaked at $22.6M in Q3 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

  • Decheng Capital reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Decheng Capital sold 694,254 Phathom Pharmaceuticals shares in Q1 2025, an estimated $5.64M.
  • Decheng Capital first reported a position in Phathom Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Decheng Capital's Phathom Pharmaceuticals position peaked at $22.6M in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Decheng Capital's 13F filing for Q1 2025, filed 8 May 2025.